Silver Member: Sarepta Therapeutics

Our vision is to transform how the world approaches the treatment of serious and life-threatening diseases by unlocking the potential of RNA-based technologies.

Recognizing the complexity of this goal, we focus on rare, infectious and other diseases with tremendous unmet needs—areas in which new therapies have the potential to make dramatic improvements in the lives of patients.

Abcam

As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster. Abcam partners with life science organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company’s proprietary discovery platforms and world-leading, antibody expertise. By constantly innovating its binders and assays, Abcam is helping […]

Acer Therapeutics

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s product candidates are believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

Aronora

Aronora is a translational biotechnology company engaged in the early-stage commercial development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes.  Building on the company’s ground-breaking rational approaches to superior drug safety, Aronora’s product candidates have the potential to become first-in-class medical emergency therapeutics to treat life-threatening acute thrombotic vascular diseases early, in the field, even before the patient is hospitalized and the diagnosis is verified.

Cascade Chemistry

Cascade Chemistry is a Contract Research & Development Organization founded in 1980. Over the years, we have developed a reputation as a reliable and experienced partner in the pharmaceutical and specialty chemical industry.

Cascade Chemistry specializes in active pharmaceutical ingredient (API) process development, scale-up and cGMP manufacturing. Most of our chemists have advanced degrees and are capable of crafting process solutions tailored to the specific needs of our clients, while adhering to strict FDA quality standards. We offer cost effective and […]

Children’s Cancer Therapy Development Institute

For many forms of childhood cancer, we’ve seen little to no advancement in treatment options for over 30 years.

There are new discoveries made in research labs, but sadly they are rarely if ever translated into new treatments for children. The process of turning a new scientific discovery into a new treatment is tedious, time-consuming, and rarely generates big profits. Kids wait for cures in hospital beds while potential discoveries lie dormant in scientific journals. Today we still have childhood cancers […]

Elex Biotech

Ventricular Arrhythmias and Heart Failure are major causes of morbidity and mortality in the world. There is a growing need for improved therapeutics, and greater recognition that we need much more effective treatments for causes of arrhythmias rather than its symptoms or sequelae. At Elex Biotech we are taking a unique rational approach toward developing new compounds that modulate the function of calcium channels that control the contraction of cardiac muscle. The strength of cardiac muscle contraction is a major […]

PDX Pharmaceuticals

PDX Pharmaceuticals started in 2010 as a spinoff from the Biomedical Engineering Department at OHSU. The company has developed novel cancer therapeutics by combining nanotechnology and cancer systems biology in collaboration with the Knight Cancer Institute (KCI) of OHSU. PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE™) and is raising $15M to initiate the clinical trial of AIRISE™ in 2022 and advance ARAC™ to clinics by 2023.

Rezolute, Inc.

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.